The Food and Drug Administration has specifically raised concerns about BPC-157 impurities and the possibility that the molecule could trigger an immune reaction
Scientific References (External Links) For researchers seeking primary literature on the mechanisms described above: Journal of Investigative Dermatology: Alpha-Melanocyte-stimulating hormone and its cleavage product (KPV) downregulate inflammatory responses View Study Biomedical Research International: GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration View Study Journal of Physiology and Pharmacology: BPC 157 and blood vessels View Study Annals of the New York Academy of Sciences: Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues View Study
Who should avoid IGF-1 LR3 Certain individuals should not use IGF-1 LR3 under any circumstances: Absolute Contraindications : Active cancer or history of hormone-sensitive tumors Severe diabetes or uncontrolled blood sugar Pregnancy or nursing mothers History of organ enlargement Active blood clotting disorders Relative Contraindications (may require specialty medical clearance): History of diabetes Cardiovascular conditions Autoimmune disorders Kidney or liver dysfunction History of growth disorders Before starting IGF-1 LR3, comprehensive health screening is essential
Research applications include wound healing, collagen synthesis, antioxidant gene activation, and fibroblast stimulation
But because glutathione helps recycle other antioxidants like vitamin C and vitamin E, it frees them up to be re-used to remove free radicals and decrease oxidative stress
The Testing Timeline Baseline (before starting): Run all the tests below that match your goals, 1-2 weeks before your first dose
